Pharma in Focus: Key Findings from the CPHI community
Explore what the CPHI community has to say about the top trends emerging from the pharmaceutical industry and supply chain with our annual Strategic Insights infographic.
As we gear up for CPHI Frankfurt and celebrate 10 years of the CPHI Insights Lounge, we once again asked our CPHI community members for their insights and opinions on the top trends shaping the pharmaceutical landscape.
This infographic compiles the responses of over 150 respondents and their thoughts on major trends, challenges, and opportunities facing the pharmaceutical industry today.
Continued and growing interest in AI technologies, sustainability and Green Chemistry, and innovative biopharmaceutical products and services top the list of major industry hot spots. However, challenges remain in areas such as regulatory harmonisation, technological adoption, and cost constraints for pharmaceutical companies and their partners alike.
As the global pharma community comes together for 3 days of brainstorming and innovative solutions in Frankfurt, this infographic highlights the power of collaborative work and partnerships in fostering the kind of solutions the industry needs right now.
Your insights continue to guide us in creating events that truly serve the industry, and bringing expert insight on what you most want to learn about. To learn more, explore the full infographic here or below:
-1.png)
-2.png)
-3.png)
-4.png)
-5.png)
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...